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Abstract Background The reporting of thyroid carcino-
mas follows the recommendations of the College of
American Pathologists (CAP) protocols and includes pap-
illarycarcinoma,follicularcarcinoma,anaplasticcarcinoma
and medullary carcinoma. Despite past and recent efforts,
there are a number of controversial issues in the classiﬁca-
tion and diagnosis of thyroid carcinomas (TC) that,
potentially impact on therapy and prognosis of patients with
TC. Discussion The most updated version of the CAP thy-
roid cancer protocol incorporates recent changes in
histologic classiﬁcation as well as changes in the staging of
thyroid cancers as per the updated American Joint Com-
mission on Cancer staging manual. Among the more
contentious issues in the pathology of thyroid carcinoma
include the deﬁning criteria for tumor invasiveness. While
there are deﬁned criteria for invasion, there is not universal
agreement in what constitutes capsular invasion, angioin-
vasion and extrathyroidal invasion. Irrespective of the
discrepant views on invasion, pathologists should report on
the presence and extent (focal, widely) of capsular invasion,
angioinvasion and extrathyroidal extension. These ﬁndings
assist clinicians in their assessment of the recurrence risk
andpotentialformetastaticdisease.Itisbeyondthescopeof
this paper to detail the entire CAP protocol for thyroid
carcinomas; rather, this paper addresses some of the more
problematic issues confronting pathologists in their assess-
ment and reporting of thyroid carcinomas. Conclusion The
new CAP protocol for reporting of thyroid carcinomas is a
step toward improving the clinical value of the histopatho-
logic reporting of TC. Large meticulous clinico-pathologic
and molecular studies with long term follow up are still
needed in order to increase the impact of microscopic
examination on the prognosis and management of TC.
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Introduction
Despite advances in the last several decades in the diagnosis
of thyroid cancers, there are still many problems and con-
troversies related to the histopathology of thyroid
carcinomas. These controversies impact on the prognosis
and therapy of thyroid cancer patients, as well as, on the
development of cutting edge research aimed at better out-
comeandqualityoflifeforthesepatients.Thesecontentious
issues may directly impact on the pathologic reporting of
thesecarcinomas.InthemostupdatedversionoftheCollege
of American Pathologists (CAP) protocol for the examina-
tion of specimens from patients with carcinomas of the
thyroid, attempts were made to address some of these con-
troversies. The goal was to produce a practical document
providing for more clinically relevant pathology reports.
The updated CAP protocol is essentially organized in a
similar fashion to the previous edition with some modiﬁ-
cations primarily but not exclusively based on the current
CAP recommendations for the reporting of all cancers.
Among the controversial issues in thyroid pathology
include (but are not limited to) the histopathologic inter-
pretation of an encapsulated (well-differentiated) thyroid
follicular neoplasm, speciﬁcally in determining which of
these lesions does and which does not represent the
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Controversies also relate to the concept of the less com-
monly occurring poorly-differentiated thyroid carcinoma. It
is beyond the scope of the CAP protocol to provide
guidelines for the histopathologic interpretation of thyroid
cancers. Among the standard data elements required by the
CAP, this paper addresses speciﬁc issues pathologists will
confront relative to criteria of malignancy (e.g., invasive-
ness) and extrathyroidal extension (ETE). Unfortunately,
even among the authors of the updated CAP Thyroid Cancer
Protocol there was not uniformity in agreement on these
issues. As such, the document echos the varying views on
invasiveness and ETE. Although listed as recommended
rather than required elements, mitotic activity and necrosis
are important in potentially determining whether a given
cancer represents a poorly-differentiated thyroid carcinoma.
Finally, the issue of whether the identiﬁcation of thyroid
papillary microcarcinomas should engender the use of the
CAP Thyroid Cancer Protocol will be discussed.
The updated CAP thyroid protocol is still a work in
progress and a ﬁnal consensus among the responsible
authors has not been reached on all of the reporting data
elements, including (but not limited to): (1) whether to
report all identiﬁable foci of thyroid papillary microcarci-
noma including incidentally identiﬁed foci or whether to
limit reporting to only those foci that were detectable pre-
operatively (by clinical examination and/or radiographic
evaluation); (2) whether to limit the use of the designation
of thyroid papillary microcarcinoma to adults excluding
such a designation for pediatric age groups. Consequently,
the recommendations herein contained reﬂect the views of
the author of this manuscript, as well as the senior author of
the CAP protocol (Bruce M. Wenig MD
1). Modiﬁcations to
the recommendations in this manuscript based on a ﬁnal
consensus opinion of the entire panel may yet occur.
Discussion
Criteria and Extent of Capsular and Vascular Invasion
in Follicular Carcinoma and its Variants
Capsular Invasion (CI)
The diagnosis of papillary thyroid carcinoma is entirely
predicated on the presence of diagnostic nuclear features.
As such, the diagnosis of papillary thyroid carcinoma can
be made in the presence of an encapsulated follicular
neoplasm even in the absence of invasive growth. Once a
given neoplasm invades its capsule and/or shows evidence
of angioinvasion (intracapsular or beyond), that follicular
epithelial cell lesion is malignant.
Excluding papillary thyroid carcinoma, there is universal
agreement that the diagnosis of follicular carcinoma
requires the presence of capsular or vascular invasion of the
tumor capsule or beyond the tumor capsule. Unfortunately,
there is still controversy in regard to the interpretation of CI.
While most authors require complete capsular transgression
by tumor in order to diagnose capsular invasion [3, 4], other
authorities will diagnose a given neoplasm as a carcinoma
even in the presence of incomplete capsular transgression
[5]. According to Chan [3], Fig. 1 depicts the various his-
tologic appearances associated with the presence or absence
of capsular invasion. According to this author [3], a given
neoplasm should not be diagnosed as carcinoma if complete
capsular penetration cannot be proven after extensive
sampling except in one instance. This situation occurs when
a satellite tumor nodule morphologically similar to the main
tumor is lying just outside the tumor capsule (Fig. 1e). This
appearance results from failure to identify the point of
capsular penetration. It is noteworthy that not all authors
agree that these satellite nodules represent CI [6]. In
equivocal cases of CI, the entire cancer irrespective of
tumor size should be processed in the attempt to clarify
whether CI is present. Deeper sections of the representative
parafﬁn block(s) should be performed in the areas of con-
cern in order to exclude CI [3].
Angioinvasion or Lymph-Vascular Invasion
The CAP guidelines for all cancer protocols calls for the
use of the term lymph-vascular invasion (LVI) which is the
terminology used in the Thyroid Cancer Protocol as well as
all the protocols for the reporting of carcinomas of the
entire upper aerodigestive tract, including the oral cavity,
pharynx (oro-, naso- and hypopharynx), sinonasal tract,
larynx and salivary glands.
While the criteria for capsular invasion are quite contro-
versial, there is currently relatively good consensus on what
constitutes lymph-vascular invasion. The majority of
authors agree that lymph-vascular invasion should involve
capsular or extra-capsular vessels (Fig. 2). These images
(Fig. 2) depict intracapsular LVI with endothelialized
thrombus, tumor thrombus with ﬁbrin, and tumor thrombus
attachedtovesselwall.Thetumorthrombusshouldprotrude
into the lumen and needs to be covered by endothelial cells
(Fig. 2b). However, endothelialization is not a requirement
if the tumor is attached to the vessel wall (Fig. 2c) or
admixed with a ﬁbrin thrombus (Fig. 2d). The point of
attachmentofthetumortothevesselwallhastobeidentiﬁed
for some authorities [7] to assure that free ﬂoating tumor
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not misinterpreted as LVI. Tumor in intra-tumoral or sub-
capsular vessels does not qualify for LVI and should not be
interpreted as such (Fig. 2a).
Extent of Capsular and Lymph-Vascular Invasion
Follicular carcinomas of the thyroid gland, including its
oncocytic variant (so-called Hu ¨rthle cell carcinoma), are
subdivided into minimally and widely invasive carcinomas
[4]. There is general agreement that follicular carcinomas
with widespread gross invasion of the thyroid and peri-thy-
roid soft tissue should be labeled as widely invasive
follicularcarcinoma[3,4].Thesetumorsoftenlackcomplete
encapsulation and have a poor prognosis [3]. In contrast, the
criteria deﬁning ‘‘minimally invasive’’ follicular carcinoma
are controversial and still evolving. In some schemes, this
designationrefers toencapsulatedlesions withcapsularand/
or small caliber sized LVI even if the LVI is extensive [4].
Theinvasivefociintheselimitedinvasivecancersarerarely,
if ever, grossly identiﬁable. Deﬁned as such minimally
invasive follicular carcinomas have an overall good prog-
nosis although some cases may recur and metastasize [5, 8].
Identifying these ‘‘minimally invasive’’ follicular carcino-
mas may be crucial as some surgeons take a conservative
management approach and treat these cancers by lobectomy
alone followed by observation. Such an approach is held for
all ‘‘minimally invasive’’ follicular carcinomas, including
the oncocytic (Hu ¨rthle cell) category. However, the thera-
peuticapproachforthediagnosisofanyfollicularcarcinoma
whether minimally invasive or not generally includes total
thyroidectomy and post-operative radioactive iodine (RAI)
therapy. Itshouldbe noted that the conservative approach of
lobectomyandobservationmayriskundertreatingthosefew
minimally invasive tumors with a poor outcome. In order to
detect those ‘‘minimally invasive’’ cases that recur, some
authorities limit the use of the minimally invasive term to
those carcinomas with capsular invasion only since their
metastaticrateiscloseto0[9,10].Thedesignation‘‘grossly
encapsulated angioinvasive follicular carcinoma’’ has been
suggested to encapsulated tumors with any foci of vascular
invasion in view of their perceived higher risk of recurrence
[11].TheseauthorsfeelthatthepresenceofLVI,eveninone
or a few endothelial-lined vessels, negates a diagnosis of
‘‘minimalinvasion’’asthesecarcinomasoncegainingaccess
to any vessel have the capacity to behave in a more aggres-
sive manner than those carcinomas with only capsular
invasion without LVI [11]. Other authors base their deﬁni-
tion of minimally invasive carcinoma on the number of foci
of invasion especially vascular invasion. [10, 12–14]. In
some studies, encapsulated follicular carcinoma, including
the oncocytic variant, with four or more foci of vascular
invasion have a signiﬁcant recurrence rate (47% for follic-
ular oncocytic tumors) even if the foci of angioinvasion are
microscopic [13, 14] (Fig. 3). These tumors are therefore
called ‘‘grossly encapsulated follicular carcinoma with
extensive angioinvasion’’. Another study showed that fol-
licular oncocytic (Hu ¨rthle cell) carcinomas with a total of
two foci of capsular/vascular invasion did not recur after a
long follow up and should therefore be labeled as minimally
invasive [12].
Irrespective of one’s philosophy in regard to the deﬁ-
nition of minimally invasive follicular carcinoma, the
recommendation is that pathologists should report on the
presence as well as the extent (focal, extensive) of capsular
and lymph-vascular invasion. This approach has a dual
advantage of collating the various terminologies suggested
for these carcinomas, as well as and perhaps more impor-
tantly, providing a report that better assists the clinician in
Fig. 1 Capsular invasion (CI): Schematic drawing for the interpre-
tation of the presence or absence of CI. The diagram depicts a
follicular neoplasm (orange) surrounded by a ﬁbrous capsule (green).
a bosselation on the inner aspect of the capsule does not represent CI;
b sharp tumor bud invades into but not through the capsule suggesting
invasion requiring deeper sections to exclude; c: tumor totally
transgresses the capsule invading beyond the outer contour of the
capsule qualifying as CI; d: tumor clothed by thin (probably new)
ﬁbrous capsule but already extending beyond an imaginary (dotted)
line drawn through the outer contour of the capsule qualifying as CI;
e: satellite tumor nodule with similar features (architecture, cytomor-
phology) to the main tumor lying outside the capsule qualifying as CI;
f Follicles aligned perpendicular to the capsule suggesting invasion
requiring deeper sections to exclude g follicles aligned parallel to the
capsule do not represent CI; h mushroom-shaped tumor with total
transgression of the capsule qualiﬁes as CI; i mushroom-shaped tumor
within but not through the capsule suggests invasion requiring deeper
sections to exclude; j neoplastic follicles in the ﬁbrous capsule with a
degenerated appearance accompanied by lymphocytes and sidero-
phages does not represent CI but rather capsular rupture related to
prior ﬁne needle aspiration. Modiﬁed from: Chan JKC. Reprinted
with permission [3]
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extent of surgical intervention (e.g., completion thyroid-
ectomy) and the use of postoperative RAI therapy.
Mitosis and Tumor Necrosis
Increased mitotic activity and especially tumor necrosis are
powerful indicators of adverse outcome in thyroid carci-
nomas of follicular origin. Asklen and Livolsi showed that
tumor necrosis and mitotic rate[2 mitosis/10 high power
ﬁelds indicate worse survival in papillary thyroid carcinoma
(P = 0.028; P\0.00005, respectively) [15]. Mitosis and
tumor necrosis are also strongly associated with poorly
differentiated thyroid carcinomas (PDTC). The latter type
of carcinoma has a prognosis in between the indolent well
differentiated papillary thyroid carcinomas and the almost
universally lethal anaplastic carcinoma. Its deﬁnition is
however subject to controversy. PDTC deﬁned on the basis
of high mitotic activity (C5 mitosis/10 high power ﬁelds,
4009) and/or tumor necrosis have a disease speciﬁc sur-
vival of 60% at 5 years irrespective of the tumor
architecture (Fig. 4)[ 16]. PDTC deﬁned mainly on the
Fig. 2 Vascular invasion (VI): Schematic drawing for the interpre-
tation of the presence or absence of VI. The diagram depicts a
follicular neoplasm (green) surrounded by a ﬁbrous capsule (blue).
a Bulging of tumor into vessels within the tumor proper does not
constitute VI. b Tumor thrombus covered by endothelial cells in
intracapsular vessel qualiﬁes as VI. c Tumor thrombus in intracap-
sular vessel considered as VI since it is attached to the vessel wall.
d Although not endothelialized, this tumor thrombus qualiﬁes for VI
because it is accompanied by a ﬁbrin thrombus. e Endothelialized
tumor thrombus in vessel outside the tumor capsule represents VI.
f Artefactual dislodgement of tumor manifesting as irregular tumor
fragments into vascular lumen unaccompanied by endothelial cover-
ing or ﬁbrin thrombus. Modiﬁed from: Chan JKC Reprinted with
permission [3]
Fig. 3 Encapsulated follicular carcinoma (FC), oncocytic variant
with multiple foci of microscopic vascular invasion (VI) and no gross
invasion. In some classiﬁcation schemes, these tumors are labeled as
minimally invasive while others will use terms such as encapsulated
angioinvasive FC or encapsulated FC with extensive angioinvasion to
stress their potential for aggressive behavior. This 50 year old patient
developed bone metastases 10 years after thyroidectomy. a Low
power view showing multiple microscopic foci of VI in tumor capsule
(arrow) and immediately outside the capsule. b high power view of a
tumor thrombus (arrow) attached to vessel wall and covered by
endothelial cells
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the large Italian study by Volante et al.) also occupy an
intermediate position at the prognostic level on the spec-
trum of thyroid carcinoma progression [17]. However,
when Volante et al. developed a numeric scoring system
whose most inﬂuential parameter was tumor necrosis, those
neoplasms with necrosis had a much worse survival than
those without [17]. Indeed, the overall survival curve of
their most favorable subgroup even overlapped with that of
patients with well-differentiated papillary and follicular
carcinomas [17]. The overall survival of their most
aggressive group (those patients whose neoplasms con-
tained at least tumor necrosis) appears to be closer to that of
PDTC deﬁned by necrosis and/or a high mitotic rate [17].
Recently, a group of pathologists gathered in Turin, Italy in
the attempt to provide a consensus view regarding PDTC
[18].Their deﬁnition relied on the presence of solid growth
but required the presence of at least one of the followings:
convoluted nuclei, tumor necrosis and/or mitosis C3/10
high power ﬁelds, 4009. In this study as well, mitosis and
tumor necrosis were very powerful indicator of poor out-
come (P = 0.011; P\0.001 respectively) while the type
of PDTC (papillary vs non-papillary) was not. The value of
mitosis and tumor necrosis is also emphasized by the fact
that PDTC deﬁned on the basis of mitoses and/or necrosis is
the major cause of radioactive iodine (RAI) refractory,
positron emission tomography (PET)-positive incurable
thyroid carcinomas [19]. The importance of tumor necrosis
in primary tumors is further validated by the fact that it was
(along with extra-thyroid extension) the only independent
variable associated with decreased overall survival within
RAI refractory thyroid carcinomas [19].
From the above data, one can conclude that whatever
deﬁnition is used for PDTC, it is very helpful to mention the
presence of mitosis and tumor necrosis in the pathology
report. It is however important to differentiate tumor
necrosis fromnecrosis due toprevious ﬁne needle aspiration
(FNA). Tumor necrosis has a ‘‘comedo-like’’ appearance
composed of degenerating cytoplasm and punctuate,
karyorectic nuclear debris (Fig. 4). In contrast, the presence
of ﬁbroblastic stromal reaction, evidence of hemorrhage or
an identiﬁable needle tract in the necrotic area are attrib-
utable to reaction induced by prior FNA. Since the majority
of thyroid cancers are well-differentiated lacking mitotic
activity and necrosis, and the fact that PDTC is a rather
uncommon diagnosis, the Thyroid Cancer Protocol recom-
mends rather than requires the reporting of these data
elements (i.e., mitotic activity and tumor necrosis).
Extra-Thyroid Extension
Extrathyroidal extension refers to involvement of the peri-
thyroidal soft tissues by a primary thyroid cancer. On gross
examination, the capsule may appear complete but evidence
has shown that microscopically the capsule is focally
incomplete in a majority of autopsy thyroid glands evalu-
ated [20]. The capsule includes sizable vascular spaces as
well as small peripheral nerves and is continuous with the
pretracheal fascia. [21]. In practice, since the ﬁbrous cap-
sule of the thyroid is often incomplete, the criteria for
Fig. 4 Tumor necrosis in
thyroid carcinoma with various
growth patterns. a Follicular
growth pattern with tumor
necrosis (N). b Papillary
architecture with necrosis (N).
c Tumor with a predominantly
solid growth pattern and a large
area of necrosis (N). d Tumor
with an insular pattern. Necrosis
was present elsewhere in the
specimen. Reproduced with
permission from Hiltzik et al.
[14]
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lematic and subjective. Diagnostic ﬁndings for minimal
extrathyroidal extension includes the presence of carcinoma
extending into perithyroidal soft tissues, including inﬁltra-
tion of adipose tissue and skeletal muscle, as well as around
(and into) sizable vascular structures and nerves. Extension
into adipose tissue can be problematic given the fact that
adipose tissue can be found within the thyroid gland proper
under normal conditions and also may be a component of a
variety of thyroid lesions including carcinomas. [22]. As
such, the presence of adipose tissue in association with a
thyroid carcinoma should not be mistaken for extrathyroidal
extension. Some authorities only accept invasion of skeletal
muscle as the identiﬁer for extrathyroidal extension. How-
ever, similar to adipose tissue in the thyroid, the presence of
skeletal muscle may be seen in the thyroid gland under
normal conditions, especially in relation to the isthmus
portion of the thyroid gland, as well as in a variety of
pathologic conditions [22]. If present, a desmoplastic
response may be a helpful ﬁnding in the determination of
extrathyroidal extension (Fig. 5). The identiﬁcation of
thick-walled vascular spaces and/or small peripheral nerves
in association with adipose tissue may be of greater assis-
tance as these structures are not located in the thyroid gland
proper and their presence would be helpful in determining
whether the carcinoma is extrathyroidal in extent (Fig. 5).
While minimal extra-thyroid extension can be difﬁcult
to identify, extensive extra-thyroid extension is always
obvious and easily diagnosed by the surgeon during the
thyroidectomy. Extensive extrathyroid extension is deﬁned
by the presence of carcinoma well beyond the thyroid
gland proper with direct invasion (i.e., not metastasis) into
one or more of the following structures:subcutaneous soft
tissues; adjacent viscera, including the larynx, trachea and/
or esophagus; the recurrent laryngeal nerve, carotid artery
or mediastinal blood vessels. Many studies have shown that
carcinomas with extensive extra-thyroid extension have a
much worse survival than those with minimal extra-thyroid
extension [3, 23]. Moreover, some studies have found a
similar outcome in patients with minimal versus no extra-
thyroid extension [23].
Based on the above data, it is therefore mandatory to
report on the extent (minimal versus extensive) of extra-
thyroid extension.
Resection Margins
Few published studies have addressed the inﬂuence of
margin status and patient outcome. Most surgeons, endo-
crinologists, and nuclear medicine specialists require
knowledge of positive margins, i.e., tumor extending to
surgical resection edge. While this makes intuitive sense
and it is recommended that a positive margin be mentioned
in the ﬁnal pathology report, meticulous studies on the
effect of positive margins and outcome in large series of
patients with long-term follow-up are lacking.
At the present time, there is no need to report the dis-
tance of tumor to closest resection margin. Indeed, there is
no data to date on the prognostic value of close margins as
an independent or co-variable.
Lymph Node Metastases
Although controversy still exists in regard to the prognostic
value of nodal metastases in papillary thyroid carcinomas,
the reporting on lymph node status is mandatory since
positive nodal metastases most often lead to RAI therapy.
The pathologist should also comment on the presence or
absence of extranodal extension since the latter was shown
to increase the risk for distant metastases and death [24].
Papillary Thyroid Microcarcinoma
This variant of papillary thyroid carcinoma is deﬁned as any
focus measuring B1 cm. [4] Such papillary thyroid micro-
carcinomas usually are incidentally identiﬁed in thyroid
glands removed for other reasons. There is general agree-
ment that no additional therapy is needed for these
incidentally identiﬁed foci of thyroid papillary microcarci-
noma and, in order to avoid overtreatment, it is worthwhile
to consider indicating in the pathology report that these foci
have an extremely favorable prognosis and should not be
used as a reason for additional therapy (e.g., completion
thyroidectomy and RAI). Given their rather common
identiﬁcation in all thyroid gland resections and their
indolent biologic behavior, it is not the recommendation of
Fig. 5 Minimal extra-thyroid extension (ETE) into peri-thyroid fat.
The focus of ETE (between arrows) has a desmoplastic reaction (pale
staining ﬁbrous tissue). Note nearby thick walled blood vessel (V).
Both ﬁndings are indicative of ETE
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each case in which incidental papillary thyroid microcar-
cinomas are found. An exception to such practice would be
considered in those examples of papillary thyroid carcino-
mas measuring B1 cm but representing the primary reason
a lobe/gland was removed. The tumor could have been
discovered clinically (palpable, visible nodule) or by
imaging. Given the more sophisticated diagnostic (e.g.,
imaging) modalities currently available, smaller (i.e.,
\1 cm) lesions are being identiﬁed and resected. In such
circumstances, where the primary reason for thyroid sur-
gery is to excise a subcentimeter focus of PTC, then
reporting should follow the CAP Thyroid Protocol.
Although usually extremely indolent, papillary thyroid
microcarcinomas may exceptionally behave aggressively
with spread to lymph node or distant sites [25]. Such
aggressive papillary thyroid microcarcinomas usually har-
bortheirmetastasesatpresentation[25].Thepresenceoftwo
or more foci of papillary thyroid microcarcinonas, and
aggressive features related to the primary tumor such as
lymph-vascular invasion, extra-thyroid extension and
‘‘aggressive’’ morphology (e.g., tall cell features) may trig-
ger full blown treatment including total thyroidectomy and
RAI therapy. Such management does not appear to be jus-
tiﬁed at this time as there is insufﬁcient data in the literature
(long term follow-up) on these papillary thyroid microcar-
cinomas with ‘‘aggressive’’ features in the primary to justify
such a therapeutic approach. It is our recommendation that
the designation of papillary thyroid microcarcinoma should
notbeappliedtochildrenandadolescentsunder19 yearsold
as a signiﬁcant number of these subcentimeter papillary
carcinomas occurring in the pediatric population display
extrathyroidal extension and distant metastases [26].
Conclusion
The updated CAP protocol is a step toward improving the
clinical value of the pathologic reporting of thyroid carci-
nomas. An accurate assessment of the extent of invasion of
the tumor capsule, especially lymph-vascular invasion, is
an important element in the reporting of thyroid carcino-
mas. Meticulous microscopic examination of TC is no
longer an academic exercise but a necessity in the man-
agement of these malignancies. Proliferative assessment of
the tumor (i.e., mitosis and necrosis) is of high prognostic
value in the determination of a poorly-differentiated thy-
roid carcinoma. The extremely indolent behavior of
papillary thyroid microcarcinoma should be communicated
to the clinician in order to avoid overtreatment.
There are still unresolved issues in the histopathologic
diagnosis of thyroid carcinomas. Large clinico-pathologic
studies with long term follow up are still needed in order to
increase the impact of histopathology on the prognosis and
management of TC. With the advent of molecular diag-
nostics the anticipation is that many of these controversial
issues will be resolved but until that time, pathologists
must rely on morphology in the assessment and reporting
of thyroid carcinomas.
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